kristoff@GENBANK.BIO.NET (Dave Kristofferson) (03/08/91)
$$R10 BEGIN HD-91-07 FULL-TEXT *****************************************
COOPERATIVE CONTRACEPTIVE DEVELOPMENT RESEARCH CENTERS
PROGRAM
RFA AVAILABLE: HD-91-07
P.T. 34; K.W. 0413002, 0750020, 0710100
National Institute of Child Health and Human Development
Letter of Intent Receipt Date: March 25, 1991
Application Receipt Date: June 17, l991
OVERVIEW
The National Institute of Child Health and Human Development
(NICHD) invites applications from investigators willing to
participate with the NICHD under a Cooperative Agreement in
establishing a Centers program designed to conduct
comprehensive research to develop new methods to regulate
fertility. The aim of these Centers will be to conduct a
wide range of research activities that, with time, will
result in clinically useful products. The scope of the
proposed program must involve the concurrent development
of at least three projects. Each project comprises
activities related to the development of a specific method
for fertility regulation. Thus, research dealing with the
development of a compound for male fertility regulation
would be classified as a single project. Investigators are
invited to propose development of methods, other than
abortion related, that can serve the needs of the American
public.
It is the intent of NICHD to establish three Contraceptive
Development Research Centers. Grantee institutions in the
United States that meet the requirements are eligible to
participate.
The Public Health Service (PHS) is committed to achieving the health
promotion and disease prevention objectives of "Healthy People 2000," a
PHS-led national activity for setting priority areas. This Request for
Applications (RFA), Cooperative Contraceptive Development Research
Centers Program, is related to the priority area of Family Planning.
Potential applicants may obtain a copy of "Healthy People 2000" (Full
Report: Stock No. 017-001-00474-0) or "Healthy People 2000" (Summary
Report: Stock No. 017-001-00473-1) through the Superintendent of
Documents, Government Printing Office, Washington, D.C. 20402-9325
(telephone 202-783-3238).
MECHANISM OF SUPPORT
The funding mechanism to be used to assist the scientific
community in establishing these Centers will be the U54
Cooperative Agreement between the participating Centers and
NICHD. The major difference between a Cooperative Agreement
and a research grant is that there will be substantial
programmatic involvement of NICHD staff above and beyond the
levels required for traditional program management of
grants. It is expected that up to three (3) applications
will be funded for a five (5) year period, contingent upon
the receipt of a sufficient number of meritorious proposals,
within the total cost limit of $2,000,000 available for the
first year of this program.
REVIEW PROCEDURES
A preliminary review will be done by NICHD staff upon
receipt of the applications. Any application that does not
meet the minimal requirements of this RFA will be judged to
be unresponsive to this RFA and will be returned to the
applicant without technical review. Applications that are
complete and responsive may be subjected to a triage
procedure by peer review to determine their general
competitiveness. Applications judged to be competitive for
awards will be reviewed in detail in accordance with
established NIH peer review procedures for research grants.
Project site visits are neither planned nor a prerequisite
of the review procedure. The review will be conducted first
for scientific and technical merit by a special review
committee convened specifically for this purpose by the
Division of Scientific Review, NICHD. This will be followed
by a second-level review by the National Advisory Child
Health and Human Development Council in September
1991.
SPECIAL INSTRUCTIONS FOR INCLUSION OF WOMEN AND MINORITIES
IN CLINICAL RESEARCH STUDIES
For projects involving clinical research, NIH requires
applicants to give special attention to the inclusion of
women and minorities in study populations. If women or
minorities are not included or adequately represented in the
study populations for clinical studies, a specific
justification for this exclusion or inadequate
representation must be provided. Applications without such
documentation will not be accepted for review.
Application Procedures:
Applications must be submitted on form PHS 398 (revised
10/88, reprinted 9/89), which is available in most
institutional business offices and from the Office of
Administrative Management, Division of Research Grants, NIH,
Office of Grants Inquiries, Westwood Building, Bethesda,
Maryland 20892, (301) 496-744l.
Additional Information:
Potential applicants are encouraged to request a detailed
RFA by telephoning:
Gabriel Bialy, Ph.D.
Contraceptive Development Branch
National Institute of Child Health and Human Development
Executive Plaza North, Room 600
Bethesda, MD 20892
Telephone: (301) 496-l661
After receipt of the RFA, Principal Investigators who plan
to respond to this RFA should indicate so by writing to the
above address as soon as possible, but not later than March
25, 1991. The Intent letter should provide the names of the
Principal Investigator, other key investigators and
organizations that will be part of the Center's application.
This program is described in the Catalog of Federal Domestic
Assistance No. 93.864, Population Research. Awards will be
made under the authority of the Public Health Service Act
301 (42 USC-241) and 441 (USC289d) and administered under
PHS Grant Policies and Federal Regulations 42 CFR Part 52
and 45 CFR Part 74. This program is not subject the
intergovernmental review requirements of Executive Order
12372 or Health Systems Agency review.
$$R10 END **************************************************************
$$R11 BEGIN HD-91-10 FULL-TEXT *****************************************
EFFECT OF SPECIFIC COMPONENTS OF HUMAN MILK ON THE NURSLING
RFA AVAILABLE: HD-91-10
P.T. 34; K.W. 0750015, 0775015, 1003008, 0760020, 0760025
National Institute of Child Health and Human Development
Application Receipt Date: July 24, 1991
The Public Health Service (PHS) is committed to achieving the health
promotion and disease prevention objectives of Healthy People 2000, a
PHS-led national activity for setting priority areas. This RFA, Effect
of Specific Components of Human Milk on the Nursling, is related to the
priority areas of Nutrition and Maternal and Infant Health. Potential
applicants may obtain a copy of "Healthy People 2000" (Full Report:
Stock No. 017-001-00474-0) or "Healthy People 2000" (Summary Report:
Stock No. 017-001-00473-1) through the Superintendent of Documents,
Government Printing Office, Washington, D.C. 20402-9325 (telephone
202-783-3238).
The Endocrinology, Nutrition, and Growth Branch of the Center for
Research for Mothers and Children of the National Institute of Child
Health and Human Development (NICHD) invites research grant applications
on the effects of specific components of human milk on the nursing
infant with respect to nutrition, physiological maturation of specific
tissues or organ systems, and susceptibility to infection and
malignancies, endocrinopathies, and degenerative disorders. Of
particular interest are studies designed to determine the mechanisms of
these effects.
BACKGROUND
Over the last twenty years we have become aware that human milk is a
complex mixture which contains many substances besides those which meet
the classical nutritional requirements of newborn infants. Many of
these substances are not present in cow milk or infant formula or are
present there only in much lower concentrations. They include enzymes,
hormones, growth factors, antibodies, specific proteins of other
classes, non-protein nitrogenous substances, and oligosaccharides. Some
of these substances which are of large molecular size can nevertheless
be absorbed intact from the immature gastrointestinal tract. Many of
them have powerful biological actions in other in vivo and in vitro
contexts, but for only a few have we learned the physiological import of
their presence in milk. Whether the others have significant
developmental effects on the nursing infant or are only incidental
passengers of the milk secretion process is unknown.
RESEARCH GOALS
Most full-term infants thrive on artificial formulas which lack high
concentrations of the human milk-specific components. Their development
apparently proceeds satisfactorily without any specific stimulation
these substances may provide. On the other hand, the maturation of low
birth weight infants proceeds less smoothly, and is complicated by
conditions such as the respiratory distress syndrome, bronchopulmonary
dysplasia, and necrotizing enterocolitis which seem to result from
maturational deficiencies. An understanding of how human milk
components influence intestinal maturation, lung function, intellectual
development, specific or nonspecific immunity, and other variables in
the neonatal period could lead to specific therapeutic uses of these
components in physiologic or pharmacologic doses in undersized, ill, or
developmentally delayed infants. Such studies could also provide
important, broadly applicable information about the biological functions
of these components.
This RFA is issued to encourage investigators to undertake clinical
studies of the role of specific components of human milk in normal
development and disease resistance, and to develop animal or
organ/tissue models when studies in humans are impractical or unethical.
Nonclinical model studies must focus on the effects of components of
human milk. Studies of these topics are expected to increase our
understanding of the physiologic role and pharmacologic potential of
human milk components, and lead to improved formulas for artificially
fed infants. This is an underinvestigated area of research on
maternal-infant interactions, with potentially important clinical
applications.
SPECIAL INSTRUCTIONS FOR INCLUSION OF WOMEN AND MINORITIES IN CLINICAL
RESEARCH STUDIES
For projects involving clinical research, NIH requires applicants to
give special attention to the inclusion of women and minorities in study
populations. If women or minorities are not included or adequately
represented in the study populations for clinical studies, a specific
justification for this exclusion or inadequate representation must be
provided. Applications without such documentation will not be accepted
for review.
MECHANISM OF SUPPORT
Applications in response to this RFA will be funded through the
traditional individual research award (RO1) program of the NIH. This
announcement is for a single competition with the application receipt
deadline of July 24, 1991. The earliest possible start date for these
grants is March 1, 1992. It is anticipated that four (4) grants will be
awarded under this program, contingent upon receipt of a sufficient
number of meritorious applications and the availability of funds.
$600,000 has been set aside to fund these grants.
REVIEW PROCEDURES AND CRITERIA
Applications will be reviewed by NICHD staff for responsiveness to the
$$XID NIHGUIDE 19910308 V20N10 P2O2 ************************************
applicant may resubmit the application and have it assigned for review
in the same manner as unsolicited grant applications. If the
application submitted in response to this RFA is substantially similar
to a research grant application already submitted to the NIH for review,
but has not yet been reviewed, the applicant will be asked to withdraw
either the pending application or the new one. Simultaneous submission
of identical applications will not be allowed, nor will essentially
identical applications be reviewed by different review committees.
Therefore, an application cannot be submitted in response to this RFA
that is essentially identical to one that has already been reviewed.
This does not preclude the submission of substantial revisions of
applications already reviewed, but such applications must include an
introduction addressing the previous critique.
Criteria for the initial review will include the significance and
originality of research goals and approaches; the feasibility of
research and adequacy of the experimental design; the research
experience and competence of the investigator(s) to conduct the proposed
work; the adequacy of investigator effort devoted to the project; and
the appropriateness of the project duration and cost relative to the
work proposed. Following review by the Initial Review Group,
applications will be evaluated by the Institute's Advisory Council for
program relevance and policy issues before awards for meritorious
proposals are made.
INQUIRIES
Requests for copies of the complete RFA should be directed to:
Ephraim Y. Levin, M.D.
Medical Officer, Endocrinology, Nutrition and Growth Branch
Center for Research for Mothers and Children
National Institute of Child Health and Human Development
Executive Plaza North, Room 637
Rockville, MD 20852
Telephone: (30l) 496-5593
For fiscal and administrative matters, contact:
Mr. E. Douglas Shawver
Office of Grants and Contracts
National Institute of Child Health and Human Development
Executive Plaza North, Room 501
Rockville, MD 20852
Telephone: (301) 496-1303
This program is described in the catalog of Federal Domestic Assistance
No. 93.865, Research for Mothers and Children. Awards will be made
under the authority of the Public Health Service Act, Section 301 (42
USC241), and administered under PHS grant policies and Federal
Regulations 42 CFR Part 52 and 45 CFR Part 74. This program is not
subject to review by a Health Systems Agency.
$$R11 END **************************************************************
$$R12 BEGIN CA-91-11 FULL-TEXT *****************************************
MINORITY ONCOLOGY LEADERSHIP ACADEMIC AWARD
RFA AVAILABLE: CA-91-11
P.T. 34, FF; K.W. 0785140, 0745020, 0745027, 0745070, 0755030, 0795003
National Cancer Institute
Letter of Intent Receipt Date: April 5, 1991
Application Receipt Date: May 17, 1991
PURPOSE
The Comprehensive Minority Biomedical Program, Division of Extramural
Activities, National Cancer Institute (NCI), invites academic health
centers or schools and other health professional schools that employ,
educate or serve a preponderance of minority faculty, staff, trainees
and communities, to submit applications for the support of an individual
to pursue leadership activities in the development of research and
training programs in clinically oriented cancer research (defined as
including population research; surgical, medical or radiation oncology;
cancer prevention and control; epidemiology and biostatistics;
nutrition; clinical pharmacology and clinical trials; behavioral
medicine and related areas of cancer research).
GOALS AND SCOPE
This award is aimed at encouraging and assisting a designated leader in
any of the minority health professional schools to increase his/her
institution's efforts in clinical cancer research in the areas such as
medical oncology, prevention, etiology, diagnosis, treatment, and
control; and to aid in establishing a cadre of faculty and staff capable
of developing new research protocols and of participate in intervention
studies and clinical trials in these areas.
These awards offer opportunities for supporting start-up expansion of
such activities, and are intended to meet needs that have not been
addressed by other types of awards available from the NCI or other
Federal Agencies. Priority is given to those minority institutions with
an interest in and commitment to expansion of clinical cancer
research-related activities in local populations.
MECHANISM OF SUPPORT
Support of this program will be through the National Institutes of
Health grant-in-aid (KO7). Applicants will be responsible for the
planning, direction, and execution of the proposed project. Up to
$350,000 in total costs per year will be committed specifically to fund
applications submitted in response to this RFA. It is anticipated that
between 2 and 4 awards will be made from the competition for this K07
solicitation. This funding level is dependent on the receipt of a
sufficient number of applications of high scientific merit. The
earliest feasible start date for the initial award is September 30,
1991. Awards may be requested for a period of 3 to 5 years.
LETTER OF INTENT
Prospective applicants are asked to submit, by April 5, 1991, a letter
of intent that includes a descriptive title of the proposed research,
the name and address of the Principal Investigator, the names of other
key personnel, the participating institutions, and the number and title
of the RFA in response to which the application is being submitted. The
letter of intent is of great benefit to the NCI in planning for and
implementing the review process although it is not required, is not
binding, and does not enter into the review of subsequent applications.
The letter of intent should be sent to the NCI Program Director:
Dr. Lemuel Evans
Comprehensive Minority Biomedical Program
Division of Extramural Activities
National Cancer Institute
NIH Building 31, Room 10A04
Bethesda, MD 20892
Telephone: (301) 496-7344
FAX: (301) 402-0062
For information regarding budgetary/administrative issues related to
this RFA, please contact:
Mr. Leo Buscher, Jr.
Chief, Grants Administration Branch
National Cancer Institute
National Institutes of Health
Executive Plaza South, Room 216
Bethesda, MD 20892
Telephone: (301) 496-7753
INQUIRIES
Requests for a complete copy of the RFA, written or telephone inquiries
concerning the objectives and scope of this RFA, or inquiries about
whether or not specific proposed research would be responsive should be
directed to Dr. Lemuel Evans at the above address. The Program Director
welcomes the opportunity to clarify any issues or questions from
potential applicants.
$$R12 END **************************************************************
$$R13 BEGIN CA-91-12 FULL-TEXT *****************************************
CLINICAL INVESTIGATOR AWARD FOR RESEARCH ON SPECIAL POPULATIONS
RFA AVAILABLE: CA-91-12
P.T. 34; K.W. 0715035, 0411005, 0715020, 0785055, 0785140, 0785210,
0745062
National Cancer Institute
Letter of Intent Receipt Date: April 5, 1991
Application Receipt Date: May 17, 1991
PURPOSE AND BACKGROUND
The Comprehensive Minority Biomedical Program, Division of Extramural
Activities, National Cancer Institute (NCI) announces the availability
of Clinical Investigator Awards for Research on Special Populations.
This program is intended to:
o Encourage newly trained clinicians to develop research interests and
skills in the basic and applied sciences relevant to cancers and risks
for cancers that have a high prevalence or incidence in special
populations that may be underserved by limited access to current
knowledge and medical care.
o Increase the pool of cancer physician-investigators, particularly in
medical oncology, epidemiology, nutrition, behavioral medicine, surgical
oncology, preventive oncology and diagnostic and therapeutic radiology,
who are committed to investigation of the unique problems facing special
populations.
o Provide the opportunity for clinically trained physicians with a
commitment to research to develop into independent biomedical research
investigators.
The term "special populations" refers to those population segments which
may experience or are known to experience high cancer rates and are
underserved in terms of: cancer prevention and control programs (e.g.,
smoking or health screening programs); diagnostic and treatment
modalities; study for special risk factors or underlying biological
differences; and who may have limited access to regular medical care.
This definition is taken to include: African Americans, Alaskan
Natives, American Indians, Asian Americans, Pacific Islanders, the
elderly, Hispanics, and low-income groups.
HEALTHY PEOPLE FOR THE YEAR 2000
The Public Health Service (PHS) is committed to achieving the health
promotion and disease prevention objectives of Healthy People 2000, a
PHS-led national activity for setting priority areas. This PA/RFA,
"Clinical Investigator Award for Research on Special Populations (K08)",
is related to the priority area of cancer research. Potential
applicants may obtain a copy of Healthy People 2000 (Full Report: Stock
No. 017-001-00474-0) or Healthy People 2000 (Summary Report: Stock No.
017-001-00473-1) through the Superintendent of Documents, Government
Printing Office, Washington, D.C. 20402-9325 (Telephone 202-783-3238).
GOALS AND SCOPE
The award will enable candidates to undertake from three to five years
of specialized study and supervised research experience tailored to
individual needs with a sponsor (or sponsors) competent to provide
research guidance. This award is intended to cover the transition
between postdoctoral experience and a career in independent
investigation, and to acquaint the candidate with the often unique
challenges and circumstances involved in designing research protocols
directed toward improving the health of groups comprising a significant
and often disproportional percentage of individuals at risk from high
cancer morbidity and mortality rates.
This award differs from the NIH Research Career Development Award (RCDA)
in that it seeks to develop research ability in individuals with a
clinical background early in the candidate's career rather than to
promote the further development of research skills of individuals
already demonstrating significant research achievement. A major purpose
of this award is to increase the number of cancer-oriented research
physicians in the United States with research interests and experience
focused specifically on the unique needs of special populations and the
broad array of issues at the biological, behavioral, social, economic
and medical levels that render such populations at increased risk for
cancer and for mortality from cancer.
SPECIAL INSTRUCTIONS FOR INCLUSION OF WOMEN AND MINORITIES IN CLINICAL
RESEARCH STUDIES
For projects involving clinical research, NIH requires applicants to
give special attention to the inclusion of women and minorities in study
populations. If women and/or minorities are not included or adequately
represented in study populations proposed for clinical studies, a
specific justification for this exclusion or inadequate representation
must be provided. Applications without such documentation will not be
accepted for review.
MECHANISM OF SUPPORT
Support of this program will be through the National Institutes of
Health grant-in-aid (K08). Applicants will be responsible for the
planning, direction, and execution of the proposed project. Applicants
may request three to five years of support. Awards are non-renewable
and non-transferable from one awardee to another. Funding beyond the
first year of the grant is contingent on satisfactory progress during
the preceding year. Future program interest in this initiative will be
announced through the NIH program announcement mechanism.
It is anticipated that in a majority of cases the experience and results
achieved by awardees as a result of this special grant program will
provide the basis for their successful competition in the research
support programs of the NCI.
Up to $300,000 has been set-aside in FY 1991 to fund meritorious
applications received in response to this competition. Depending on the
merit and distribution of applications received, approximately 1 to 3
Clinical Investigators will be funded with a start date of September 30,
1991. Meritorious applications received for this competition that
cannot be funded at that time may be held over for possible funding in
fiscal year 1992.
LETTER OF INTENT
Prospective applicants are asked to submit, by April 5, 1991, a letter
of intent that includes a descriptive title of the proposed research,
the name and address of the Principal Investigator, the names of other
key personnel, the participating institutions, and the number and title
of the RFA in response to which the application is being submitted. The
letter of intent is of great benefit to the NCI in planning and
implementing the review process although the letter is not required, is
not binding, and does not enter into the review of subsequent
applications. The letter of intent must be sent to the NCI Program
Director:
Dr. Lemuel Evans
Division of Extramural Activities
Comprehensive Minority Biomedical Program
National Cancer Institute
Building 31, Room 10A04
Bethesda, MD 20892
Telephone: (301) 496-7344
For information regarding budgetary/administrative issues related to
this RFA, please contact:
Mr. Leo Buscher, Jr.
Chief, Grants Administration Branch
National Cancer Institute
National Institutes of Health
Executive Plaza South, Room 216
Bethesda, MD 20892
Telephone: (301) 496-7753
INQUIRIES
Requests for a copy of the complete RFA, written or telephone inquiries
concerning the objectives and scope of this RFA or inquiries about
whether or not specific proposed research would be responsive should be
directed to Dr. Lemuel Evans at the above address. The program director
welcomes the opportunity to clarify any issues or questions from
potential applicants.
$$R13 END **************************************************************
$$R14 BEGIN CA-91-13 FULL-TEXT *****************************************
MINORITY SCHOOL FACULTY DEVELOPMENT AWARD
RFA AVAILABLE: CA-91-13
P.T. 34, FF; K.W. 0715035, 0710030
National Cancer Institute
Letter of Intent Receipt Date: April 5, 1991
Application Receipt Date: May 17, 1991
PURPOSE
The Comprehensive Minority Biomedical Program, Division of Extramural
Activities, National Cancer Institute (NCI), invites academic health
centers or schools and other health professional schools that employ,
educate or serve a preponderance of minority faculty, staff, trainees
and communities to submit applications for support of activities
directed at the development of faculty investigators at minority schools
in areas relevant to cancer. The intent of the award is to provide the
awardee with increased access to research opportunities through
collaborative arrangements with outstanding cancer research scientists,
usually at institutions within a 100 mile radius of the applicant
organization.
BACKGROUND
Despite a variety of efforts to increase minority faculty
representation, the percentage of minority faculty in U.S. medical and
other health professional schools has remained at consistently low
levels. The continuation of this deficiency is projected by observing
the discrepancies between the proportion of underrepresented minorities
in the medical school population and the general population. While 12
percent of the U.S. population is African American, less than 1 percent
of persons holding a Ph.D. in science are African American and the
percentages for other minority groups are correspondingly small.
The proportion of minority biomedical investigators, especially those
receiving funding support from agencies of the Federal government, is
strikingly low. This program is designed to offer support for cancer
related research to minority school faculty members at the M.D., Ph.D.
or equivalent level who have the interest and capabilities of doing
state-of-the-art research in this area.
GOALS AND SCOPE
The objective of this Request for Applications (RFA) is to broaden the
experience of faculty members at minority schools, increase the pool of
biomedical and behavioral investigators in cancer research, and have
graduate and undergraduate students, most of whom will be minority
individuals, become more cognizant of research opportunities in cancer
research.
MECHANISM OF SUPPORT
Support of this program will be through the National Institutes of
Health grant-in-aid (K14). Applicants will be responsible for the
planning, direction, and execution of the proposed project. Except as
otherwise stated in this RFA, awards will be administered under PHS
grants policy as stated in Public Health Service Grants Policy
Statement, HHS Publication No. (OASH) 90-50,000, revised October 1,
1990. Applicants may request three to five years of support. Awards
are non-renewable and nontransferable from one awardee to another.
Funding beyond the first year of the grant is contingent on satisfactory
progress during the preceding year. Future program interest in this
initiative will be announced through the NIH program announcement
mechanism.
A set-aside of approximately $300,000 in total costs per year has been
designated for this group of applications, which should request a
starting date of September 30, 1991. It is anticipated that three to
four awards will be made. This funding level is dependent upon the
receipt of a sufficient number of applications of high scientific merit.
Although this program is provided for in the financial plans of the NCI,
the award of grants pursuant to this RFA is also contingent upon the
availability of funds for this purpose.
LETTER OF INTENT
Prospective applicants are asked to submit by April 5, 1991, a letter of
intent that includes descriptive title of the proposed research, the
name and address of the Principal Investigator, the names of other key
personnel, the participating institutions, and the number and title of
the RFA in response to which the application is being submitted. The
letter of intent is of great benefit to the NCI in planning and
implementing the review process.
INQUIRIES
Requests for a copy of the complete RFA, written or telephone inquiries
concerning the objectives and scope of the RFA or inquiries about
whether or not specific proposed research would be responsive should be
directed to:
Dr. Lemuel A. Evans
Director
Comprehensive Minority Biomedical Program
National Cancer Institute
Building 31, Room 10A04
9000 Rockville Pike
Bethesda, MD 20892
For information regarding budgetary/administrative issues related to
this RFA, please contact:
Mr. Leo Buscher, Jr.
Chief, Grants Administration Branch
National Cancer Institute
National Institutes of Health
Executive Plaza South, Room 216
Bethesda, MD 20892
Telephone: (301) 496-7753
The Program Director welcomes the opportunity to clarify any issues or
questions from potential applicants, and to aid in identification of
institutions and potential mentors appropriate top the interests of the
applicant.
$$R14 END **************************************************************
$$R15 BEGIN AI-91-08 FULL-TEXT *****************************************
RESEARCH UNITS ON PELVIC INFLAMMATORY DISEASE AND ITS SEQUELAE
RFA AVAILABLE: AI-91-08
P.T. 34; K.W. 0715026, 1002004, 1002027, 0710070
National Institute of Allergy and Infectious Diseases
Letter of Intent Receipt Date: April 15, 1991
Application Receipt Date: October 21, 1991
The Sexually Transmitted Disease Branch of the Division of Microbiology
and Infectious Disease of the National Institute of Allergy and
Infectious Diseases (NIAID) invites grant applications for program
project grants to be initiated in FY 1992 that focus on pelvic
inflammatory disease (PID) and its sequelae. In recognition of the
severe impact of PID on the health of women, the NIAID wishes to expand
research in this area and to place greater emphasis on investigations
that are likely to lead to reduction of the incidence and severity of
long-term sequelae such as infertility, ectopic pregnancy and chronic
pelvic pain syndrome. The Research Units on PID and its Sequelae will
provide a strong, interdisciplinary approach to PID research which will
draw upon expertise in clinical, epidemiological, behavioral, and basic
sciences. Although a broad range of PID research issues will be
addressed, research in the following three areas is particularly
enthusiastically encouraged:
1) Long-term sequelae - Characterization of the immunopathological and
behavioral determinants of the development of long-term sequelae of PID
and use of animal models to evaluate interventions to reduce these
sequelae;
2) Atypical PID - Development of methods to detect atypical infections
and definition of the epidemiology of this portion of the PID spectrum;
3) Diagnostic Approaches - Development and assessment of non-invasive
methods to diagnose PID.
The Public Health Service (PHS) is committed to achieving the health
promotion and disease prevention objectives of Healthy People 2000, a
PHS-led national activity for setting priority areas. This RFA,
Research Units on Pelvic Inflammatory Disease and its Sequelae, is
related to the priority area of Sexually Transmitted Diseases.
Potential applicants may obtain a copy of "Healthy People 2000" (Full
Report: Stock No. 017-001-00474-0) or "Healthy People 2000" (Summary
Report: Stock No. 017-001-00473-1) through the Superintendent of
Documents, Government Printing Office, Washington, D.C. 20402-9325
(telephone 202-783-3238).
RESEARCH OBJECTIVES AND SCOPE
The goal of this program is to encourage investigators to undertake
research that will provide the microbiological, immunological, clinical,
epidemiological and behavioral information needed for the eventual
control of PID and its long-term sequelae. In addition to other
important research issues, data that are needed to design and conduct
intervention trials to reduce the incidence and severity of sequelae of
PID are of high priority. It should be understood that such a trial is
not a component of this solicitation nor has the NIAID developed
specific plans for such a trial at this time. However, one of the major
purposes of this RFA is to stimulate exceptionally high quality,
multi-disciplinary research on those aspects of the epidemiology,
pathogenesis and detection of PID that are likely to be critical in the
design of such trials.
In addition to the importance of utilizing a multi-disciplinary
approach, specific programmatic requirements and constraints are as
follows:
o Structure: Each program project must consist of at least three
individual subprojects that are synergistically inter-related. Each
subproject should clearly describe research objectives and each should
be headed by a Principal Investigator, with a research staff and a
separately identifiable budget.
o Clinical Facility: In order to bridge the basic research and clinical
arenas, the PID program project must offer a strong clinical facility
with accessible patient populations that are appropriate to answering
PID research questions. Adolescents and inner city minority groups
should be considered for special attention in the context of these
program project grants.
SPECIAL INSTRUCTIONS FOR INCLUSION OF WOMEN AND MINORITIES IN CLINICAL
RESEARCH STUDIES - For projects involving clinical research, NIH
requires applicants to give special attention to the inclusion of women
and minorities in study populations. By the nature of this program,
subjects will consist largely of women. Applicants are urged to give
added attention, where feasible and appropriate, to the inclusion of
minorities in study population for PID program project grants. If
minorities are not included or adequately represented in the study
populations for clinical studies, a specific justification for this
exclusion or inadequate representation must be provided. Applications
without such documentation will not be accepted for review.
A broad range of research questions is potentially relevant to the goal
of this program. Specific research areas of high priority include but
are not limited to microbiology, pathogenesis, epidemiology, behavioral
determinants, and diagnosis of PID and are addressed in greater detail
in the RFA.
MECHANISM OF SUPPORT
Successful applicants funded under this RFA will be supported through
program project (PO1) grants. This type of funding mechanism is
utilized when it is desired to encourage multi-disciplinary
investigator-initiated research on a broad range of problems which are
linked by a common theme. NIAID anticipates making three program
project grant awards as a result of this RFA. The final number of
awards to be made is dependent upon the availability of funds. Requests
for support should be limited to no more than $800,000 total costs for
the initial year of funding. This solicitation represents a single
competition with a specified deadline for receipt of applications.
Awards will be made for a project period of up to four years. Although
there are no present plans to reissue this RFA at any future time, NIAID
may invite competitive renewal applications upon expiration of the
initial funding period, contingent on the availability of funds for this
purpose.
ELIGIBILITY - ONLY DOMESTIC INSTITUTIONS ARE ELIGIBLE TO APPLY.
APPLICATION PROCEDURE
Before preparing an application, the prospective applicant must request
a copy of the RFA and the NIAID Information Brochure on Program Project
Center Grants from:
Dr. Judith Wasserheit
Chief, Sexually Transmitted Diseases Branch
Westwood Building, Room 749
Division of Microbiology and Infectious Diseases
National Institute of Allergy and Infectious Diseases
National Institutes of Health
9000 Rockville Pike
Bethesda, MD 20892
Telephone: (301) 402-0443
Letter Of Intent
Prospective applicants are asked to submit, by April 15, 1991, a letter
of intent that includes a descriptive title and the names and
affiliations of the proposed key investigators for each of the proposed
research projects.
This letter must be sent to:
Dr. Olivia Preble
Chief, Microbiology and Immunology Review Section
Program and Project Review Branch
National Institute of Allergy and Infectious Diseases
National Institutes of Health
Westwood Building, Room 3A10
Bethesda, MD 20892
Telephone: (301) 496-8208
Questions regarding fiscal matters should be addressed to:
Mr. Todd Ball
Grants Management Branch
Division of Extramural Activities
NIAID, NIH
Westwood Building, Room 726
Bethesda, MD 20892
Telephone: (301) 496-7075
$$R15 END **************************************************************
FULL TEXT OF RFAs FOR ONLINE ACCESS